Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

Single-Use Technologies: Driving Aseptic Innovation

As single-use technologies gain traction in aseptic manufacturing, they’re transforming production flexibility, cost-efficiency, and contamination risk management. Learn why these systems are becoming the industry standard.
  • GMP, GxP
Adopting single-use technologies involves higher upfront costs and waste management issues, necessitating careful regulatory compliance and evaluation of production needs and budgets.

Biosimilars: Opportunities and Challenges

As the demand for affordable, effective treatments grows, biosimilars offer promising solutions in healthcare. Explore the potential, challenges, and regulatory landscape shaping this expanding market
  • GxP
Biosimilars are biologic medicines that are highly similar to an existing FDA-approved biologic, known as the “reference product.”

Contamination Control Strategy: A Guide to Creating an Effective Plan

A robust contamination control strategy is vital in regulated industries to maintain safety and compliance. Discover key components, documentation practices, and best strategies to reduce contamination risks.
  • GMP, Quality Management System
A contamination control strategy serves as a foundational plan for maintaining a clean environment

Patient-Centric Approaches in Clinical Trials

Clinical trials are undergoing a transformative shift, with a growing focus on patient-centric approaches. This change prioritizes patient needs and convenience by integrating digital health solutions, making trials more accessible, efficient, and aligned with today’s healthcare landscape.
  • Quality Management System
Remote monitoring technologies enhance patient-centric trials by enabling real-time data collection from patients at home, improving convenience and data quality.

AI in Drug Development: Transforming the Future of Medicine

Artificial Intelligence (AI) is reshaping the pharmaceutical industry, optimizing drug discovery, clinical trials, and personalized medicine. Learn how AI is accelerating the drug development process and improving patient outcomes.
  • Quality Management System
AI and machine learning are being applied specifically to drug discovery, showcasing some real-world examples and the potential future impact on healthcare.

Are Packaging Materials a Hidden Source of Nitrosamines? Understanding the Risks

Packaging materials can be a potential source of nitrosamines, either through the migration of these compounds from the packaging into the drug product or through chemical reactions that occur within the packaging environment.
  • Nitrosamine
Quality professionals inspecting diverse packaging materials for the presence of nitrosamines in pharmaceutical products, within a clean and controlled environment.

EU GMP Annex 1: Your Guide to Contamination Control

Explore the essential distinctions that exist between the previous version and the most recent updates of the EU GMP Annex 1 guidelines. Understand how these changes play a critical role in shaping the practices of sterile pharmaceutical manufacturing. Additionally, examine
  • GMP, GxP
The revised EU GMP Annex 1 modernizes sterile manufacturing with technology and a risk-based approach, improving product quality and patient safety.

Risk Assessment vs Confirmatory Testing of Nitrosamine Formation in Pharmaceuticals

Balancing risk assessment and confirmatory testing for nitrosamines is a complex task that requires a deep understanding of both the product and the processes involved in its manufacture. By creating a thorough risk assessment, gathering sufficient scientific data, ensuring analytical
  • Nitrosamine
Risk Assessment vs Confirmatory Testing of nitrosamine formation in pharmaceuticals